Objective: To assess the outcome of endovascular repair (EVAR) of small abdominal aortic aneurysms (AAA, Յ5.5 mm maximum diameter) in Australia. Results: The 30-day mortality and technical success rates were 1.1% and 98%, respectively. Postoperative complications occurred in 29%. Survival was 84% and 52% at 3 and 5 years, respectively. Primary, assisted primary, and secondary clinical success rates were 72%, 79%, and 82%, respectively, at 3 years. Reintervention rate was 11% at 3 years; however, 15% of patients continued to have significant aortic sac enlargement. Survival was reduced in patients considered unfit for general anesthesia (odds ratio ϭ 2.6; 95% confidence interval, 1.4 -4.8, P ϭ 0.002) or those who had elevated preoperative serum creatinine (odds ratio ϭ 2.0; 95% confidence interval, 1.3-3.0, P ϭ 0.001). Conclusions: EVAR can be carried with good perioperative outcome in patients with small AAA; however, intermediate success is hampered by the need for reintervention and continued aortic sac enlargement. At present, widespread treatment of small AAAs by EVAR would appear inappropriate. (Ann Surg 2007;245: 326 -333) A bdominal aortic aneurysm (AAA) affects approximately 5% of men and 1% of women over 60 years, and the incidence is increasing.
A bdominal aortic aneurysm (AAA) affects approximately 5% of men and 1% of women over 60 years, and the incidence is increasing. 1 The principal complication of AAA is aortic rupture, which usually results in death. 2 Rupture risk is presently best predicted by aortic diameter, with AAAs Ͼ6 cm having a rupture risk of approximately 10% per year.
Since AAA is usually asymptomatic, the condition is often diagnosed as an incidental finding during abdominal imaging. Recently, a number of randomized controlled trials have demonstrated that ultrasound screening of selected population can reduce deaths associated with AAA. 4, 5 The more widespread use of ultrasound screening and abdominal imaging has led to an increase in the number of small AAAs referred for management. Two randomized trials have supported a conservative policy for small AAAs, whereby following identification aneurysms are followed by ultrasound surveillance unless the aneurysm expands to Ͼ5.5 cm in maximal diameter when surgery is advised. 6, 7 The introduction of endovascular aneurysm repair (EVAR) has made available a less invasive surgical option, which had been demonstrated to be associated with lower perioperative mortality than open surgery for the repair of large aneurysms. 8, 9 However, EVAR has a number of complications that only become apparent during longer-term follow-up, such as late aortic rupture, endoleak, graft migration, and graft limb occlusion. 10, 11 Intermediate follow-up of patients randomized to EVAR for the treatment of large AAAs demonstrated no reduction in allcause mortality in comparison to open surgery and increased requirement for reintervention. 10, 11 The favorable perioperative results, the greater anatomic suitability and the belief that the outcome of EVAR is better have all encouraged the extension of this technique to patients normally treated conservatively with small AAAs. The aim of this study was to examine the perioperative and intermediate results of EVAR for AAAs of Յ5.5 cm.
METHODS

Australian Audit of Endovascular Repair of AAA
In Australia EVAR is performed by specialist vascular surgeons. In 1999 the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP-S) was commissioned to carry out an independent national audit of EVAR with prospective entry of procedures performed from November 1999 to May 2001. The audit was part of an interim establishment of Medical Benefits Schedule numbers for the procedure; thus, participation was initially enforced. As a result, high rates of surgeon participation have been seen with cross checks with Health Insurance Commission data, suggesting that more than 90% of procedures are included. 12 Data were collected prospectively on standardized discharge and follow-up forms available from the ASERNIP-S office (or http://www.surgeons.org/asernip-s/audit.htm). Information collected included preoperative characteristics of the patient and aneurysm, procedural details, in-hospital complications, reinterventions, readmission, mortality, and follow-up imaging, as previously described. 12, 13 All data entry was double checked, including confirming source data accuracy with other information resources, such as the National Death Index (Australian Institute of Health and Welfare) and the Health Insurance Commission. Comorbidities were defined by patient histories obtained by the local vascular consultant. 12, 13 Hypertension, diabetes mellitus, ischemic heart disease, and chronic obstructive airways disease were recorded when patients had a history of previous symptoms, which had been investigated and confirmed by objective evidence usually requiring treatment, such as medication or interventions. Symptoms of cerebrovascular and peripheral vascular disease were specifically sought by the local specialist and confirmed by clinical examination and appropriate imaging. Renal function was measured by recording serum creatinine, with values Ͼ120 mol/L (1.35 mg/dL) defined as renal impairment. Cigarette smoking history was defined by questioning patients. Assessment of CT angiograms was carried out by the local treating consultant vascular surgeon. Assessments provided to ASERNIP-S included maximal aortic diameter measured from the CT angiograms and presence of endoleak (I-IV). 12, 13 No core laboratory was used.
Assessment of Outcome for Patients With Small AAA
To assess the outcome of EVAR for small AAAs in Australia, data were obtained from ASERNIP-S for the 478 subset of patients undergoing repair of an AAA measuring Յ55 mm in maximal diameter. The outcome for the total group of 961 patients registered during the recruitment stage of the audit has been previously presented. 12, 13 Despite repeat requests, data forms were missing entries in a small number of fields up to a maximum of 35 (7%) cases.
Outcomes and Follow-up
The outcome measures used were procedural technical success, all-cause and aneurysm-related mortality, in-hospital complications, reinterventions, clinical success, endoleaks, and changes in aortic diameter. Technical, primary, assistedprimary, and secondary clinical success were calculated according to reporting standards established by the Ad Hoc Committee for standardized reporting practices in vascular surgery.
14 Clinical success conventional requires: 1) successful deployment of the endograft; and 2) absence of aneurysmrelated death, type I or III endoleak, graft infection, thrombosis, aneurysm rupture, conversion to open, graft migration, and aneurysm expansion Ն5 mm.
14 To investigate the influence of fluctuation in aneurysm diameter during follow-up, clinical success was also reported without inclusion of the diameter requirement "absence of aneurysm expansion Ն5 mm," stated as modified clinical success. Postoperative complications were classified as device related (endoleaks types I-IV, graft thrombosis, graft migration), access site, and lower limb (wound or artery related, peripheral emboli) and systemic (cardiac, pulmonary, renal, cerebral, gastrointestinal). Reinterventions were classified as arterial (endovascular or open) or nonarterial but related. Median follow-up time for the 478 patients at the time of analysis (August 2005) was 1150 days (3.15 years; interquartile range, 887-1344 days). As a result of deaths (n ϭ 101) and losses (n ϭ 110), 56% (267 of 478) of patients were still undergoing follow-up at 3 years ( Fig. 1) . Maximum aortic diameter was recorded from the patients' preoperative or follow-up CT scan. Aortic diameters were available on approximately 87% of the patients being followed up to 3 years (Fig. 1) .
Analysis
Data were stored on a key-coded access database (Microsoft) and subsequently converted to Excel and SSPS analysis programs. Total and aneurysm-related survival, primary, assisted-primary, and secondary clinical success, freedom from arterial reinterventions, expansion of aortic diameter by Ն5 mm, and endoleak over time were calculated by Kaplan-Meier analysis. Cox proportion hazard analysis was used to assess determinants of aneurysm-related and unrelated mortality, secondary clinical success, total arterial reinterventions, Ն5 mm sac shrinkage or enlargement, type I or II endoleaks, and significant perioperative complications. Separate analysis was carried out on a subset of patients with more than 3 years follow-up of aortic diameter (n ϭ 227). Figure 1 illustrates how this cohort was defined.
RESULTS
Preoperative and Procedural Details of the Whole Group
The characteristics of the total cohort of 478 patients are illustrated in Table 1 
Perioperative Outcome and Results Within 30 Days of the Procedure
Technical success was achieved in 98% (466 of 478) of patients, with failure secondary to death (aortic rupture n ϭ 1), conversion to open (n ϭ 1), and type I endoleak (n ϭ 10). The 30-day mortality rate was 1.1% (5 of 478), with additional deaths due to myocardial infarction (n ϭ 2), bowel ischemia (n ϭ 1), and intracerebral hemorrhage (n ϭ 1) ( Table 2 ). Significant postoperative complications occurred in 29% (138 of 478) of patients; 52 procedural and devicerelated complications occurred in 11% (51 of 478) of patients, including graft thrombosis (n ϭ 4), graft migration (n ϭ 2), type I endoleak (n ϭ 10), type II endoleak (n ϭ 35), and type IV endoleak (n ϭ 1). In 20 patients, type II endoleak was the only complication. A total of 72 systemic complications were noted in 13% (64 of 478) of patients, including cardiac (n ϭ 22), pulmonary (n ϭ 17), renal (n ϭ 14), bowel (n ϭ 9), cerebral (n ϭ 5), sepsis (n ϭ 4), and hepatobiliary (n ϭ 1). A total of 41 access site and lower limb complications were observed in 8% (39 of 478) of patients, including bleeding, hematoma, or false aneurysm (nϭ 17), lymph leak or collection (n ϭ 9), peripheral emboli (n ϭ 5), wound infection (n ϭ 4), arterial thrombosis (n ϭ 3), and neuropathy (n ϭ 3). Arterial reinterventions (Յ30 days) occurred in 3% 
Intermediate Outcome
By Kaplan-Meier analysis, 84% and 52% of patients were alive 3 and 5 years, respectively, following EVAR. Aneurysm-related mortality was 2.3% at both 3 and 5 years. Causes of death are summarized in Table 2 . Primary, assisted 
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primary, and secondary clinical success was 72%, 79%, and 82%, respectively, at 3 years. Modified primary, assisted primary, and secondary clinical success was 82%, 89%, and 92%, respectively, at 3 years (Fig. 2) . Overall, 97 patients had an endoleak demonstrated during follow-up imaging. Type 1 endoleaks developed in 26 patients (10 had an associated type 2 endoleak), and type 2 endoleaks developed in 81 patients (1 had an associated type 4 endoleak) (Fig. 3) .
Diameter Changes During Follow-up
By the last imaging follow-up, maximal aortic diameter had decreased by Ն5 mm in 294 (62%) and enlarged by Ն5 mm in 44 (9%). Maximal aortic diameter was seen to fluctuate in some patients over time even where no reintervention was performed. Hence by Kaplan-Meier analysis (which considers an endpoint once a diameter cutoff is reached), the proportion of patients attaining a postoperative diameter reduction of at least 5 mm was 74% at 3 years, larger than calculated if the last imaging scan only is used (Fig. 4) . In 79 patients, maximal aortic diameter was noted to have increased by Ն5 mm from the preoperative measurement in at least one CT scan (15% by Kaplan-Meier analysis at 3 years, Fig. 4 ). In 36 of these cases, the aortic diameter was noted to subsequently reduce below the 5-mm cutoff, and in 28 cases this improvement was without reinterventions. Imaging demonstrated only one complication, a type I endoleak, in patients that spontaneously improved. Patients who improved after reintervention had the following findings on imaging: Graft migration and subsequent type 1 endoleak (3), graft thrombosis (1), type 2 endoleak (1), and no complication (3). In patients with maintained sac enlargement (Ն5 mm compared with preoperative diameter), imaging demonstrated the following complications: type 2 endoleak (13), type 1 endoleak (5), graft infection (1), and graft migration (1) . No complication was established in 23 patients.
Reinterventions in Relation to Endoleak and Sac Enlargement
A total of 50 patients underwent 72 additional arterialrelated interventions by open, endovascular, or combined 
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Repair of Abdominal Aortic Aneurysms approaches (Fig. 5) (Fig. 1) . The change in preoperative compared with 3 year imaging maximal aortic diameter is illustrated in Figure 6 . The patients who required reintervention during follow-up were more likely to have significant enlargement of the aortic sac at 3 years (9 of 32, 28%) compared with those who did not (13 of 195, 7%), P Ͻ 0.05, suggesting that despite further surgery sac expansion is maintained in some patients.
Determinants of Survival, Aneurysm-Related Mortality, Sac Expansion, Clinical Success, and Reintervention
Since the diameter criteria used in many centers for elective aneurysm repair is 50 mm, we compared the outcome of patients with 50 to 55 mm (n ϭ 336) and Ͻ50 mm (n ϭ 142) aortic aneurysms. There was no difference in terms of survival, clinical success, and reintervention. All-cause mortality was predicted by renal impairment (odds ratio ͓OR͔ ϭ 2.0; 95% confidence interval ͓CI͔, 1.3-3.0, P ϭ 0.001) and surgeons labeling of "unfit for general anesthesia" (OR ϭ 2.6; 95% CI, 1.4 -4.8, P ϭ 0.002) by Cox proportion hazard analysis with adjustment for age. The survival for patients with renal impairment was 75% Ϯ 4% and 38% Ϯ 12% at 3 and 5 years, respectively. By comparison, the survival for patients without renal insufficiency was 87% Ϯ 2% and 51% Ϯ 8% at 3 and 5 years, respectively. The survival of patients thought to be unfit for general anesthesia was 72% Ϯ 9% and 41% Ϯ 14% compared with 85% Ϯ 2% and 71% Ϯ 3% for those consider fit at 3 and 4 years, respectively. The requirement for arterial reintervention was greater in patients with peripheral vascular disease (OR ϭ 1.9; 95% CI, 1.1-3.3, P ϭ 0.03) after adjustment for age. This is likely due to the association of peripheral vascular disease with type I endoleak (OR ϭ 2.3; 95% CI, 1.1-5.0, P ϭ 0.03). Modified secondary clinical success was associated with gender (OR ϭ 1.6; 95% CI, 1.1-2.3, P ϭ 0.02) after adjustment for the type of endovascular device used. Thus, the modified clinical success was 94% Ϯ 1% and 93% Ϯ 1% for men compared with 88% Ϯ 4% and 70% Ϯ 16% for women at 3 and 5 years, respectively. Significant shrinkage of the aortic sac during follow-up was predicted by maximum preoperative aortic neck diameter Ͻ25 mm (OR ϭ 1.34; 95% CI, 1.04 -1.74, P ϭ 0.02) and lack of history of chronic obstructive airways disease (OR ϭ 1.44; 95% CI, 1.09 -1.90, P ϭ 0.01) after adjustment for age. No predictors of aneurysm-related mortality were demonstrated.
DISCUSSION
The management of abdominal aortic aneurysm measuring Յ5.5 cm is controversial, with options including conservative treatment, EVAR, or open surgery. In comparing the value of these management options, the main considerations are mortality, complications, durability, requirement for repeat interventions, and health-related quality of life. In the absence of a recognized medical therapy for aortic aneurysm, conservative management presently consists of imaging surveillance of the aneurysm and clinical follow-up with intervention planned when the aorta expands to over 50 -55 mm, depending on local protocol. This approach has the advantage of avoiding an initial operation with its associated risk of complications and perioperative incapacity, which may impact on the patient's health-related quality of life. 15 The risk of the small aneurysm rupturing during this conservative surveillance period appears to be low at Ͻ1% per year; however, this policy will just delay the inevitable for some patients (Table 3) . 7, 16 In the U.K. Small Aneurysm Trial (UKSAT), 73% of patients in the surveillance arm of the trial 
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ultimately required surgery and the likelihood of the patient being in this subgroup is determined by the rate of aneurysm growth and long-term survival. Small aneurysm growth is primarily determined by initial aortic diameter, while survival is primarily dependent on the patients' associated cardiac, cerebrovascular, or neoplastic diseases. 17 Open surgery offers the advantage of a durable repair of the aortic aneurysm (the reintervention rate in the Aneurysm Detection and Management study was Ͻ2% at 5 years); however, this approach comes with a risk of perioperative mortality and significant complications that many would feel are unacceptable (Table  3) . 6, 7, 16 EVAR offers the advantage of a relatively low risk repair of the aneurysm, which for large AAAs has been demonstrated to be safer than open surgery during the perioperative period. 8, 9 Since there are few data to support that small aneurysms are associated with less complications than large ones when repaired by open surgery, it would be expected that this advantage would also be present for small aneurysms. However, the durability of EVAR has been questioned with reports of aneurysm ruptures during follow-up. 18 Trials are presently underway to investigate the value of EVAR in the management of small AAAs but are not expected to report until late this decade. 19 In this study, we examined the outcome of EVAR for aneurysms Յ5.5 cm in a nationwide audit of this technique.
The findings of this study support EVAR as a relatively low risk procedure to repair AAAs. Despite 40% of patients being considered unsuitable for open surgery, the perioperative mortality was 1.1%. Other significant complications were, however, reported in 25% of patients. As in the endovascular management of large AAAs, we found that the main concern with EVAR was durability. The estimated arterial reintervention rate was 11% and 13% at 3 and 5 years, respectively, similar to that reported following treatment of large AAAs 10 ( Fig. 5 ). Despite this level of repeat surgery, a number of patients continued to have aortic sac expansion (Figs. 4, 6 ). By Kaplan-Meier analysis, aortic sac shrinkage, no growth, and expansion were detected in 74%, 11%, and 15%, respectively, at 3 years (Fig. 4) . The finding that 15% of patients continue to have sac expansion at 3 years following EVAR is concerning. It should be noted, however, that conclusions from one off sac measurements can be deceptive, and this should be taken into account when calculating clinical success (Fig. 2) . Previous reports of sac diameters following EVAR for small AAAs are limited. The EUROSTAR group reported a rate of small aneurysm growth following EVAR of 7% and 21% at 3 and 5 years, respectively. 20 Rates of aneurysm growth following EVAR of large AAAs have been reported to vary between 1% and 28% during intermediate follow-up, and this is partly explained by the different methods used to calculate this outcome (as illustrated in Results). 21, 22 We only detected 5 incidences of AAA rupture during follow-up, suggesting that follow-up and reintervention were generally protecting patients from severe consequences (Table 2). However, since our follow-up is limited, rupture rates for these size aneurysms is low (1.9%-3.2% at 5 years, Table  3 ), and most patients do not have postmortems, this finding should be viewed with caution. Ideally, much longer follow-up (around 10 years) is needed to detect whether EVAR can achieve long-term protection against aneurysm rupture for these size AAAs. Table 3 illustrates the results of this study in comparison to other studies analyzing the outcome of treatment of small AAAs. 6, 7, 16, 20, 23 A number of findings important in the design of a randomized trail for small aortic aneurysm are evident. Aneurysm-related mortality makes up a relatively small proportion of total mortality within 5 years. Total mortality appears to be more determined by population characteristics and therefore unlikely to be useful as an outcome measure of the management policy ( Table 3 ). The aneurysmrelated mortality estimated from ASERNIP-S and EUROSTAR for endovascular repair is around 3% at 5 years. 20 This outcome compares favorably with the 5-year outcome reported for conservative treatment by the UKSAT 7 (Table 3) . However, this comparison is deceptive, outdated, and invalid for a number of reasons, including population and follow-up differences and changing management options. 24 Thus, in the comparable Aneurysm, Detection and Management Study, the 5-year aneurysm-related mortality was reported as 2.6% for conservative treatment. 6 This variation largely reflects the difference in outcome of open aneurysm repair in these 2 populations rather the incidence of aneurysm rupture during surveillance (Table 3) . Today a large proportion of aortic aneurysm repairs are carried out by EVAR rather than by open surgery, as was the case in both UKSAT and the Aneurysm, Detection and Management Study. Thus, the number of aneurysm-related mortalities in the conservative group who come to require intervention would be reduced by comparison to UKSAT-C in a similar study today. It should be noted that all 3 studies reporting outcome of EVAR for small aneurysms in Table 3 are from registries. Since establishment of a medical benefits number was linked to the development of the ASERNIP-S audit, the collection of cases and data has been generally good by comparison to other registries. 19, 21 However, the collection of information does not approach that which can be achieved in randomized controlled trials, which are reported by way of comparison in Table 3 . 6, 7, 16 A scientific comparison of EVAR and conservative management awaits the findings from ongoing trials; however, our analysis suggests that these studies will require a large number of participants and a high postmortem rate to demonstrate whether there is any difference in aneurysmrelated mortality at 10 years.
Ultimately, the management of patients with small aortic aneurysms needs to be related to the individual. Our analysis of the determinants of outcome after EVAR suggest that patients with small AAAs and renal impairment or considered unfit for general anesthesia have limited survival. Over 50% of these patients had died at intermediate followup; therefore, in keeping with the findings of EVAR 2, it would appear inappropriate to treat small aneurysms in the majority of these patients. 25 Successful exclusion of the aneurysm was more likely in male patients and those with smaller aneurysm necks.
CONCLUSION
This study suggests that EVAR can be performed with good perioperative success in patients with small AAAs. However, a considerable reintervention rate is required and further follow-up is required to clarify the outcome of this approach given the significant proportion of patients with sac enlargement. At present, widespread treatment of small AAAs by EVAR would appear inappropriate.
